Latest News

REBOOT-CNIC: Beta-Blockers Show No Benefit Post-MI in Patients with Preserved Ejection Fraction
Written by: Radcliffe Cardiology
REBOOT-CNIC: Beta-Blockers Show No Benefit Post-MI in Patients with Preserved Ejection Fraction
RELAXIN-LA Trial: Volenrelaxin Linked to Worsening Congestion in HFpEF
Written by: Radcliffe Cardiology
RELAXIN-LA Trial: Volenrelaxin Linked to Worsening Congestion in HFpEF
High-Dose Flu Vaccine Linked to Reduced Cardiovascular Hospitalisations in Older Adults
Written by: Radcliffe Cardiology
High-Dose Flu Vaccine Linked to Reduced Cardiovascular Hospitalisations in Older Adults
Mavacamten Fails to Meet Primary Endpoints in Non-obstructive Hypertrophic Cardiomyopathy
Written by: Radcliffe Cardiology
Mavacamten Fails to Meet Primary Endpoints in Non-obstructive Hypertrophic Cardiomyopathy
MAPLE-HCM: Aficamten Outperforms Beta-Blocker in Obstructive Hypertrophic Cardiomyopathy
Written by: Radcliffe Cardiology
MAPLE-HCM: Aficamten Outperforms Beta-Blocker in Obstructive Hypertrophic Cardiomyopathy
Diagnostic Red Flags are Common in Hypertrophic Cardiomyopathy, Study Finds
Written by: Radcliffe Cardiology
Diagnostic Red Flags are Common in Hypertrophic Cardiomyopathy, Study Finds
Heart Failure's Global Economic Toll Exceeds $284 Billion, New Study Finds
Written by: Radcliffe Cardiology
Heart Failure's Global Economic Toll Exceeds $284 Billion, New Study Finds
FDA Approves Finerenone for Heart Failure with LVEF ≥40%
Written by: Radcliffe Cardiology
FDA Approves Finerenone for Heart Failure with LVEF ≥40%
Simple Risk Stratification Could Optimise Heart Failure Follow-Up and Outcomes
Written by: Radcliffe Cardiology
Simple Risk Stratification Could Optimise Heart Failure Follow-Up and Outcomes
Time in Target Ambulatory Blood Pressure Range Linked to Lower CV Risk
Written by: Radcliffe Cardiology
Time in Target Ambulatory Blood Pressure Range Linked to Lower CV Risk

External news

Written by: Academic - advance access - HF
Discordant ventilatory and efferent sympathetic responsiveness to peripheral and central chemoreflex stimulation in heart failure with reduced ejection fraction
Written by: Academic - advance access - HF
Kidney Dysfunction and Pulmonary Vascular Disease in Heart Failure with preserved Ejection Fraction
Written by: Academic - advance access - HF
Modification of the association between age and mortality in heart failure by frailty status
Written by: Academic - advance access - HF
Response to: “Feasibility, multiplicity, and the interpretation of pilot findings in SAUNA-HFpEF”
Written by: Academic - advance access - HF
Epidemiological trends in hypertrophic cardiomyopathy in adults – a Swedish nationwide registry study
Written by: Academic - open access - HF
Epidemiological trends in hypertrophic cardiomyopathy in adults – a Swedish nationwide registry study
Written by: Academic - open access - HF
Impact of multicomponent exercise training in older individuals with and without heart failure with reduced ejection fraction – the role of functional capacity and novel biomarkers
Written by: Academic - advance access - HF
Impact of multicomponent exercise training in older individuals with and without heart failure with reduced ejection fraction – the role of functional capacity and novel biomarkers
Written by: Academic - advance access - HF
Reply to: Correspondence on “Impact of contemporary guideline-directed medical therapy on secondary mitral and tricuspid regurgitation in heart failure with reduced ejection fraction”
Written by: Academic - advance access - HF
Letter regarding the article “Effects of Sauna bathing on Exercise Capacity and Muscle Function in HFpEF”